Search Results

protein subtype selectivity   Madelyn N Moore , Kelsey L Person , Abigail Alwin , Campbell Krusemark , Ezequiel Marron Fernandez de Velasco , Steven H Olson , Lauren M Slosky , et. al. loss after a year, with no plateau INAUGURATION OF AELIS FARMA NEW LABORATORY at Institut Européen de

April 2022 Ono Enters into Collaboration Agreement with Domain Therapeutics and Université de Montréal (Strasbourg, France; CEO: Pascal Neuville; “Domain”) and Université de Montréal (Québec, Canada; “UdM

Tim De Groof! It’s not often when you get the best of both worlds - nano-bodies and #GPCRs.

the Department of Biochemistry and Molecular Medicine of the Faculty of Medicine of the Université de

endothelial cells (ECs) ( Pruenster et al., 2009 ; Thiriot et al., 2017 ), including those lining bone marrow

This is the essence of de-risking GPCR programs through operational excellence. your drug discovery process from a series of disconnected efforts into a seamless, predictable, and de-risked Learn to translate your program’s internal operational precision into a compelling, de-risked narrative

A postdoc in Santiago de Compostela introduced her to GPCRs, and from there, things escalated quickly

High-affinity agonists reveal recognition motifs for the MRGPRD GPCR Chunyu Wang ,  Yongfeng Liu ,  Marion GPCR drugmaker Septerna amasses $288M in IPO Surrounded by AI bio giants, tiny startup Nabla Bio makes de

conversation dives deep into the tools now transforming receptor biology—and how they’re being used to de-orphanize

Bias can make better drugs by emphasizing beneficial signaling pathways and de-emphasizing harmful ones Emphasizing Beneficial and De-emphasizing Harmful Signaling Pathways One of the most powerful applications The angiotensin system illustrates a more nuanced application: not just de-emphasizing a harmful pathway

Member Profile Antony Boucard Professor Centro de Investigación y de Estudios Avanzados del IPN (Cinvestav AB: Favorite Taco: Taco de suadero (pronounced swa-day-ro), fatty, with meat caramelized in its own fat

Boston, MA and Santiago de Compostela, Spain — [June 3rd, 2025]  — Dr.

regulating cell proliferation, survival, chemotaxis, migration, angiogenesis, adhesion, as well as bone marrow

GPCR consulting that cuts through the noise, designing assay cascades, setting go/no-go points, and de-risking

activity and working backward to define receptor biology has proven to be a productive strategy for de-orphanization As assay technologies continue to evolve and as the de-orphanization of GPCR pharmacology  accelerates

Dimerization: Unveiling Its Role in Receptor Function and Signaling Sonja Peter , Brian Bender , Chris De

Schlander M, Hernandez-Villafuerte K, Cheng CY, Mestre-Ferrandiz J, Baumann M. Seven transmembrane receptors as nature's prototype allosteric protein: de-emphasizing the geography Protein Eng Des Sel. 2016;29(12):583-594. 47.         Crilly SE, Ko W, Weinberg ZY,Puthenveedu MA.

.; De Medina, V. S.; Majellaro, M.; Sotelo, E.; Navarro, G.; Franco, R. I.; García-Rey, A.; García-Mera, X.; Gutiérrez-de-Terán, H.; Sotelo, E.

.; Henry De Villeneuve, C.; Moraillon, A.; Ozanam, F.; Gabouze, N.; Djebbar, S.

Your pipeline depends on early, well-informed decisions that move promising candidates forward while de-prioritizing

Fluorescence Microscopy validation performed in the ONCOMET laboratory (Health Research Institute of Santiago de

Emerging direction: Treatment sequencing + guided de-escalation.

contributor article on Unveiling GPCR Priming: The Hidden Synergy in Cellular Signalling Alberto Gonzalez-Hernandez

Dimerization: Unveiling Its Role in Receptor Function and Signaling Sonja Peter , Brian Bender , Chris De

L, González A, Gioé-Gallo C, Mallo-Abreu A, Brea J, Loza MI, García-Rey A, García-Mera X, Gutiérrez-de-Terán

MSCs have several sources and they can be derived from the umbilical cord, adipose tissue, and bone marrow

De novo drug design: AI algorithms can generate new molecules with desired properties, such as binding chemical space, limiting their ability to identify truly novel chemotypes”(Thomas, Smith, O’Boyle, de

running early-stage programs, recognizing this decoupling early can sharpen dose optimization  and de-risk

Domain Therapeutics was nominated for the Trophée de l'Innovation Technologique (Technological Innovation

This week's highlight includes congrats to Omolade Otun, Chris de Graaf, Cherine Bechara, et al. for